Here are the top Institutional holders of Arrowhead Pharmaceuticals Inc. (ARWR) shares

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is 0.82% higher on its value in year-to-date trading and has touched a low of $20.67 and a high of $42.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARWR stock was last observed hovering at around $31.65 in the last trading session, with the day’s loss setting it -0.8%.

Currently trading at $30.85, the stock is -8.79% and 0.18% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.75 million and changing -2.53% at the moment leaves the stock -0.98% off its SMA200. ARWR registered -8.24% loss for a year compared to 6-month gain of 6.34%. The firm has a 50-day simple moving average (SMA 50) of $20.46 and a 200-day simple moving average (SMA200) of -$13.85.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -18.97% loss in the last 1 month and extending the period to 3 months gives it a 12.14%, and is -4.16% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.21% over the week and 5.12% over the month.

Arrowhead Pharmaceuticals Inc. (ARWR) has around 525 employees, a market worth around $3.82B and $181.74M in sales. Profit margin for the company is -163.32%. Distance from 52-week low is 49.25% and -27.38% from its 52-week high. The company has generated returns on investments over the last 12 months (-54.04%).

Arrowhead Pharmaceuticals Inc. quarterly earnings per share for the current quarter are estimated at -$0.25 with sales reaching $61.98M over the same period.The EPS is expected to shrink by -40.82% this year, but quarterly earnings will post -41.70% year-over-year.

367 institutions hold shares in Arrowhead Pharmaceuticals Inc. (ARWR), with institutional investors hold 66.33% of the company’s shares. The shares outstanding are 123.84M, and float is at 116.39M with Short Float at 7.62%. Institutions hold 63.35% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 12.81 million shares valued at $456.85 million. The investor’s holdings represent 11.95% of the ARWR Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 10.97 million shares valued at $391.25 million to account for 10.24% of the shares outstanding. The other top investors are State Street Corporation which holds 5.51 million shares representing 5.14% and valued at over $196.4 million, while JP Morgan Chase & Company holds 2.69% of the shares totaling 2.88 million with a market value of $102.73 million.

Arrowhead Pharmaceuticals Inc. (ARWR) Insider Activity

A total of 5 insider transactions have happened at Arrowhead Pharmaceuticals Inc. (ARWR) in the last six months, with sales accounting for 4 and purchases happening 1 times. The most recent transaction is an insider sale by Anzalone Christopher Richard, the company’s Chief Executive Officer. SEC filings show that Anzalone Christopher Richard sold 57,499 shares of the company’s common stock on Jan 31 at a price of $32.35 per share for a total of $1.86 million. Following the sale, the insider now owns 3.72 million shares.

Arrowhead Pharmaceuticals Inc. disclosed in a document filed with the SEC on Jan 12 that Hamilton James C (Chief Discovery/Trans Medicine) sold a total of 7,940 shares of the company’s common stock. The trade occurred on Jan 12 and was made at $36.89 per share for $0.29 million. Following the transaction, the insider now directly holds 0.21 million shares of the ARWR stock.

Still, SEC filings show that on Jan 11, Vakiener Victoria (Director) disposed off 4,720 shares at an average price of $38.10 for $0.18 million. The insider now directly holds 32,001 shares of Arrowhead Pharmaceuticals Inc. (ARWR).

Arrowhead Pharmaceuticals Inc. (ARWR): Who are the competitors?

One of the company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading 28.15% up over the past 12 months.Johnson & Johnson (JNJ) lies in the list of competitors of the Arrowhead Pharmaceuticals Inc. and is -3.55% lower over the same period from ARWRLigand Pharmaceuticals Inc. (LGND) is 7.59% up on the 1-year trading charts.